Research ExplorerPublicationsChemotherapy-induced neutropenia/febrile neutropenia prophyl...

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study

Standard

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. / Ludwig, Heinz; Bokemeyer, Carsten; Aapro, Matti; Boccadoro, Mario; Gascón, Pere; Denhaerynck, Kris; Krendyukov, Andriy; Abraham, Ivo; MacDonald, Karen.

In: FUTURE ONCOL, Vol. 15, No. 8, 03.2019, p. 897-907.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ludwig, H, Bokemeyer, C, Aapro, M, Boccadoro, M, Gascón, P, Denhaerynck, K, Krendyukov, A, Abraham, I & MacDonald, K 2019, 'Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study', FUTURE ONCOL, vol. 15, no. 8, pp. 897-907. https://doi.org/10.2217/fon-2018-0814

APA

Ludwig, H., Bokemeyer, C., Aapro, M., Boccadoro, M., Gascón, P., Denhaerynck, K., Krendyukov, A., Abraham, I., & MacDonald, K. (2019). Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. FUTURE ONCOL, 15(8), 897-907. https://doi.org/10.2217/fon-2018-0814

Vancouver

Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K et al. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. FUTURE ONCOL. 2019 Mar;15(8):897-907. https://doi.org/10.2217/fon-2018-0814

Bibtex

@article{fd0d6ed0420f4db19cf73efe0ccf7936,
title = "Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study",
abstract = "AIM: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors.PATIENTS & METHODS: MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%).RESULTS: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumor patients).CONCLUSION: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.",
keywords = "Aged, Antineoplastic Agents/adverse effects, Biosimilar Pharmaceuticals/administration & dosage, Chemotherapy-Induced Febrile Neutropenia/etiology, Female, Filgrastim/administration & dosage, Hematologic Agents/administration & dosage, Humans, Male, Middle Aged, Neoplasms/drug therapy, Prospective Studies, Treatment Outcome",
author = "Heinz Ludwig and Carsten Bokemeyer and Matti Aapro and Mario Boccadoro and Pere Gasc{\'o}n and Kris Denhaerynck and Andriy Krendyukov and Ivo Abraham and Karen MacDonald",
year = "2019",
month = mar,
doi = "10.2217/fon-2018-0814",
language = "English",
volume = "15",
pages = "897--907",
journal = "FUTURE ONCOL",
issn = "1479-6694",
publisher = "Future Medicine Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study

AU - Ludwig, Heinz

AU - Bokemeyer, Carsten

AU - Aapro, Matti

AU - Boccadoro, Mario

AU - Gascón, Pere

AU - Denhaerynck, Kris

AU - Krendyukov, Andriy

AU - Abraham, Ivo

AU - MacDonald, Karen

PY - 2019/3

Y1 - 2019/3

N2 - AIM: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors.PATIENTS & METHODS: MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%).RESULTS: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumor patients).CONCLUSION: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.

AB - AIM: This study aimed to report patterns of biosimilar filgrastim prophylaxis and outcomes of chemotherapy-induced neutropenia (CIN)/febrile neutropenia (FN) in patients with hematological malignancies or solid tumors.PATIENTS & METHODS: MONITOR-GCSF is a real-world study of 1447 cancer patients receiving CIN/FN prophylaxis with biosimilar filgrastim (solid tumors: 77.2%; hematological malignancies: 22.8%).RESULTS: Differences in prophylaxis intensity and day of initiation relative to guideline recommendations were observed. In hematology patients, higher rates of CIN and FN occurred at cycle level, and rate of FN was higher at patient level (9.1 vs 5.0% in solid tumor patients).CONCLUSION: Adequate GCSF support in hematology and solid tumor patients is important to prevent CIN/FN and related hospitalizations and chemotherapy disturbances.

KW - Aged

KW - Antineoplastic Agents/adverse effects

KW - Biosimilar Pharmaceuticals/administration & dosage

KW - Chemotherapy-Induced Febrile Neutropenia/etiology

KW - Female

KW - Filgrastim/administration & dosage

KW - Hematologic Agents/administration & dosage

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasms/drug therapy

KW - Prospective Studies

KW - Treatment Outcome

U2 - 10.2217/fon-2018-0814

DO - 10.2217/fon-2018-0814

M3 - SCORING: Journal article

C2 - 30827127

VL - 15

SP - 897

EP - 907

JO - FUTURE ONCOL

JF - FUTURE ONCOL

SN - 1479-6694

IS - 8

ER -